G
Gerald A. Faich
Researcher at Food and Drug Administration
Publications - 10
Citations - 3792
Gerald A. Faich is an academic researcher from Food and Drug Administration. The author has contributed to research in topics: Celecoxib & Diclofenac. The author has an hindex of 7, co-authored 10 publications receiving 3701 citations.
Papers
More filters
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
William B. White,Gerald A. Faich,Andrew Whelton,Clement Maurath,Nancy J Ridge,Kenneth M. Verburg,G. Steven Geis,James B. Lefkowith +7 more
TL;DR: The hypothesis of a class adverse effect of cyclooxygenase 2 specific inhibitors on the CV system is not supported and the incidences of adverse CV events such as hypertension, edema, and congestive heart failure were similar to, or significantly lower than, NSAID comparators regardless of the use of ASA.
Journal ArticleDOI
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib
TL;DR: In this paper, the authors analyzed the incidence of cardiovascular events for celecoxib, placebo, and nonsteroidal anti-inflammatory drugs (NSAIDs) in the entire controlled, arthritis clinical trial database.
Journal ArticleDOI
Effects of exposure to benzodiazepine during fetal life.
TL;DR: Examination of benzodiazepine use during pregnancy in 104,000 women whose deliveries were registered by the US public health insurance system, Medicaid, during 1980-83 concluded that the high rate of teratogenicity after heavy maternal benzodiazine use occurs with multiple alcohol and substance exposure and thus may not be due to benzdiazepine exposure.
Journal ArticleDOI
Streptococcal Pharyngitis and Acute Rheumatic Fever in Rhode Island
TL;DR: Current throat culture practices probably have little influence on treatment of streptococcal pharyngitis and control of rheumatic fever in the state.